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Self-regulated glucose-sensitive neoglycoenzyme-capped 
mesoporous silica nanoparticles for insulin delivery 
 
Mar Oroval,[a],[b] Paula Díez ,[c],[d] Elena Aznar,[b],[a] Carmen Coll, [a],[b] María Dolores Marcos,[a],[b],[e] Félix 
Sancenón,[a],[b],[e] Reynaldo Villalonga[c],[d] and Ramón Martínez-Máñez*[a],[b],[e]  
Abstract: We describe herein the preparation of glucose-sensitive 
capped mesoporous silica nanoparticles for insulin delivery. The new 
material consists of an expanded pore nanometric silica support 
grafted with 1-H-propyl-1-H-benzimidazole groups, loaded with 
fluorescein isothiocyanate-labeled insulin (FITC-Ins) and capped by 
the formation of inclusion complexes between CD-modified-glucose 
oxidase (CD-GOx) and the benzimidazole groups grafted on the 
mesoporous support. Insulin delivery from the gated material in 
simulated blood plasma was assessed upon addition of glucose. 
Glucose is transformed by GOx into gluconic acid that promoted the 
dethreating of the benzimidazole-CD-GOx inclusion complexes 
allowing cargo release. Small quantities of this support would be 
needed to release the amount of insulin necessary to decrease 




Hybrid organic-inorganic nanomaterials have attracted 
significant interest due to their unique properties resulting from 
the combination of organic and bioorganic chemistry and 
material science.[1] In this field, the design and synthesis of 
mesoporous hybrid gated materials, with the ability to be 
selectively opened upon the application of an external stimulus 
and release an entrapped cargo, has generated special interest 
to the scientific community in recent years.[2-5] These gated 
materials are composed of two main subunits: (i) a porous 
scaffold in which a certain cargo is stored and (ii) molecular, 
supramolecular or biomolecular entities grafted onto the outer 
surface, which allow control delivery of the entrapped 
payload.[6,7]  Mesoporous silica nanoparticles (MSNs) have been 
widely used as inorganic support in the construction of gated 
nanodevices. MSNs present some remarkable features as they 
are mechanically hard, biocompatible, ease to functionalize 
using well-known chemistries, have a high loading capacity and 
tunable pore size.[8–10] In fact, numerous controlled-release 
systems using mesoporous silica supports have been described 
using physical,[11-14] chemical[15-17] or biochemical[18-21] stimuli.  
From different point of view, diabetes mellitus is a chronic 
metabolic disease characterized by an accumulating 
concentration of glucose in blood and urine. This illness, which 
requires ongoing medical care and patient self-management, 
takes place when beta cells of pancreas fail to produce insulin 
(type 1) or produce it insufficiently to overcome insulin 
resistance in target tissues (type 2).[22]   Moreover, it is a major 
leading cause of mortality in industrialized countries, leading to 
severe complications, such as kidney disease, retinopathy, 
neuropathy, leg or foot amputations and heart diseases.[23] In 
healthy humans, the concentration of glucose in blood is 
controlled in a finely regulated manner to maintain glucose 
between 3.5 and 7 mM.[24] In diabetic patients, administration of 
insulin to help the body to use or store the blood glucose 
obtained from food is essential in type 1 and longstanding type 2 
diabetes patients, requiring continuous dose adjustments based 
on self-monitoring of blood glucose levels. This widely used 
therapy is not exempt of hazards. The most important risk when 
treating with insulin is hypoglycemia.[25] Extremely low blood 
sugar levels can be life-threatening resulting in seizures, 
nervous system damage and even comma. Thus, a perfect 
insulin therapy should minimize the risk of hypoglycemia while 
improving glycemic control. In this context, the design systems 
able to detect fluctuations in blood glucose concentrations and 
release insulin in a self-regulated fashion is highly desirable and 
still a challenge.[26–28]  
In this context different strategies integrated with a large 
variety of chemical approaches for insulin delivery in response to 
glucose concentration changes have been reported.[29-39] 
Nevertheless, only few MSNs based systems have been 
described for this purpose. One of the first reported examples 
was developed by Lin et al.,[40] that used MSNs capped with 
gluconic acid-modified insulin (G-Ins) and loaded with cyclic 
adenosine monophosphate (cAMP). The nanomaterial 
demonstrated to be glucose-sensitive, releasing both G-Ins and 
cAMP. Moreover, Shi and co-workers reported an insulin loaded 
mesoporous silica particles coated with GOx enzyme-multilayers 
that were cross-linked with glutaraldehyde and acted as 
gatekeepers. In the presence of glucose, GOx generated 
gluconic acid with a subsequent decrease in the environment pH. 
As a consequence, the enzyme multilayer was expanded and 
the entrapped insulin released.[41] Another example was recently 
developed by Asefa and co-workers who described the 
preparation of MSNs for insulin release by tethering insulin 
molecules onto boronic acid functionalized MSNs and then 
coating the material with a shell of the pH-sensitive polymer 
polyacrylic acid.[42] The material exhibited both pH- and glucose-
dependent release of insulin.    
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Based in these concepts and considering the multiple 
advantages of MSNs as carriers in controlled release 
applications,[43–45] we report herein the design of a new self-
regulated glucose-sensitive platform for insulin release. Our 
strategy relies on the use of β-cyclodextrin-modified enzyme 
glucose oxidase (CD-GOx) as gatekeeper in MSNs and the 
enzymatic reaction between glucose and GOx as trigger which 
induces insulin delivery.[46] This approach is simple and present 
some advantages versus other reported glucose-triggered 
insulin release, such as the storage of insulin into the pores 








Scheme 1. Schematic representation of the glucose-triggered FITC-Ins 
release from nanodevice S3. 
 
 
Results and Discussion 
 
The glucose-responsive nanomaterial. 
The designed nanodevice for controlled insulin release is shown 
in Scheme 1. The system consists of MSNs with large pores 
loaded with fluorescein isothiocyanate-labeled insulin (FITC-Ins), 
functionalized on the outer surface with 1-propyl-1-H-
benzimidazol groups and capped by CD-GOx via the formation 
of inclusion complexes between benzimidazol groups in the pore 
outlets and β-cyclodextrin groups from CD-GOx (solid S3). 
When S3 is placed in an aqueous medium, addition of glucose is 
expected to trigger insulin delivery. Glucose is recognized by 
glucose oxidase enzyme and hydrolyzed into gluconic acid 
(pKa=3.6). The generation of gluconic acid induces a local drop 
in pH that would cause the protonation of benzimidazol groups 
(pKa=5.55) on S3 and the dethreading of the inclusion 
complexes between benzimidazol and CD-GOx, finally resulting 
in the delivery of entrapped insulin yielding solid S4. 
MSNs with large pores were prepared by the two-step 
swelling incorporation method, following previous reports with 
some modifications.[47,48] Especifically, tetramethylorthosilicate 
(TMOS) and cetyltrimethylammonium bromide (CTAB) were 
used as the inorganic precursor and structure directing agent, 
respectively to obtain a nanoparticulated and mesostructured 
material (S0-1). In a second step, material S0-1 was subjected 
to a hydrothermal treatment in the presence of equal volumes of 
1,3,5-trimethylbenzene (TMB), water, and ethanol to achieve the 
pore expansion (S0-2). Then the surfactant and the pore 
expanding agent (TMB) were removed by calcination to obtain 
the final support S0-3. The calcined nanoparticles were grafted 
with 3-iodopropyltrimethoxysilane and the resulting material was 
treated with benzimidazole yielding solid S1 which contains 1-
propyl-1-H-benzimidazole groups in the surface. Subsequently, 
the pores were loaded with FITC-Ins by a diffusion process to 
give solid S2. Finally, the support was capped by the addition of 
CD-GOx to a suspension of S2 in water at pH 7.5 to yield the 
final capped solid S3, which was centrifuged and carefully 
washed with water at pH 7.5. 
 
Materials characterization. 
The prepared materials were characterized using standard 
procedures. The powder X-ray diffraction (PXRD) pattern of 
solids S0-1, S0-2, S0-3, S1 and S2 are shown in Figure 1. As 
observed, the PXRD pattern of the as-synthesized nanoparticles 
S0-1 (Figure 1, curve a) shows the three typical low-angle 
reflections of a hexagonal-ordered matrix that can be indexed as 
(100), (110) and (200) Bragg peaks. However, the regularity of 
mesopores was highly diminished after pore expansion due to 
the reorganization of the internal mesostructure, which is 
corroborated by the significant broadening and the clearly 
observed displacement of the (100) peak to lower 2θ values 
(0.976°) (Figure 1, curve b, solid S0-2). In addition, diffraction 
peaks assignable to the (110) and (200) planes disappeared. On 
the other hand, the condensation of silanol groups during the 
calcination step is reflected in a slight shift of the (100) peak to 
higher 2θ values (1.094°) (Figure 1, curve c, solid S0-3), 
corresponding to an approximate cell contraction of 11.3 Å. The 
a0 cell parameter for S0-3 was calculated to be 93.13 Å (d100= 
80.65 Å). Finally, curves d and e in Figure 1, correspond to the 
PXRD pattern of S1 and S2. The presence of the (100) peak in 
these solids indicated that besides surface functionalization and 
pore loading, the porous structure in the nanoparticles is 
preserved.  
By means of transmission electron microscopy (TEM) 
analysis the porous structure, particle size and morphology of 
the different samples was also studied. Figure 2 shows a 
representative image of the calcined scaffold S0-3, S1, S2, S3 
and S4 materials. It can be clearly seen that these nanoparticles 
show a spherical form with diameters ranging from 200 to 300 
nm. TEM images of S1, S2 and S3, also evidence that porosity 
is still retained after functionalization with 1-propyl-1-H-
benzimidazole, loading with FITC-Ins and capping with CD-GOx 
(Figure 2 b, c, d). Moreover, the TEM representative image of 
solid S4 (Figure 2f) confirms that the particle morphology and 
the porous network remained unaltered after delivery of FITC-
Ins and the detachment of CD-GOx from the surface. In addition, 
particle size and morphology of solid S3 was also studied by 
field emission scanning electron microscopy (FSEM). Figure 2e 
confirms the spherical morphology and size of solid S3 observed 
in TEM analysis (Figure 2 d). 
























Figure 1. Powder X-ray diffraction patterns of a) as synthesised nanoparticles 
S0-1, b) pore expanded nanoparticles S0-2, c) pore expanded and calcined 
nanoparticles S0-3, d) solid S1 containing 1-propyl-1-H-benzimidazole and e) 
solid S2 containing 1-propyl-1-H-benzimidazole and loaded with FITC-Ins. 
 
As a complement to PXRD and TEM, adsorption-
desorption measurements were also carried out to study the 
porous structure of the calcined nanoparticles S0-3 and solid S2 
(see Figure 3). Using the Barret-Joyner-Halenda (BJH)[49] model 
on the adsorption branch of the isotherm the pore diameter and 
pore volume were calculated (Table 1). Also, the specific surface 
was calculated by the application of the BET model.[50]  The N2 
adsorption-desorption isotherms shown in Figure 3a (calcinated 
S0-3 nanoparticles) shows that pore filling occurred over a large 
range of P/P0 indicating a wide pore size distribution. On the 
other hand, the first adsorption step appears at relative high 
pressure values (0.7 < P/P0 < 0.8) evidencing the existence of 
large pores. This step preserves a type-IV isotherm but with a 
clear H1 hysteresis loop. The total specific area was calculated 
to be 527 m2 g–1, whereas the pore size distribution curve 
(Figure 3, inset) shows a very wide pore size distribution starting 
in 4 nm and extending up to 18.5 nm, with a mean value of ca. 
11.8 nm. Futhermore, two shoulders at ca. 4.7 and 9.4 nm can 
also be appreciated. 
On the other hand, a pore volume of 0.82 cm3 g-1 and 
surface area of 302 m2 g-1 where determined for solid S2 which 
means a lower N2 adsorption when compared with the starting 
calcined material. Moreover, two main features can be 
appreciated in the pore size distribution of solid S2. One is the 
shift of the maximum towards smaller size values, as it can be 
expected from the filling of the pores. The second one is that the 
distribution becomes narrower in the area of smaller pores. This 
observation may be related with lower difficulty for the FITC-Ins 
molecules to abandon the solid from the wider pores when 
washing solid S2 during the synthesis process. Hence, the 
smaller pores will remain fully filled while the big ones may still 













Figure 2. Representative TEM images of a) calcined nanoparticles, b) solid S1, 
c) solid S2, d) solid S3 and e) solid S4 showing the porosity of the silica-based 
nanomaterials. f) FSEM image of solid S3 showing the spherical morphology 
of the nanoparticles. 
 
Table 1. BET specific surface values, pore volumes and pore sizes 








S0-3 527 1.26 11.8 
S2 302 0.82 8.9 
 
The particle size studies were completed by measuring the 
diameter of calcined nanoparticles S0-3 and the hybrid materials 
S2 and S3 by dynamic light scattering (DLS) (Figure 4, and 
Table 2). All measurements were performed in triplicate on 
previously sonicated dispersions of the nanomaterials in 
simulated blood plasma at a concentration of 0.01 mg mL-1. The 
Z potential was also determined. Functionalization with 
benzimidazol moieties and loading with FITC-Ins reduced the 
zeta potential of the nanoparticles S2 (-26.5 mV) compared to 
that of calcined S0-3 (-31.4 mV). For the final nanodevice S3, 
the surface charge was reduced even more (-17.7) compared to 
S2 as a consequence of capping with CD-GOx. In addition an 
increase of the hydrodynamic diameter after each 






functionalization step was observed which resulted in a 
hydrodynamic diameter of 426.1 nm for the final S3 nanodevice 
(see Table 2). 
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Figure 3. The nitrogen adsorption-desorption isotherms for a) calcined 
















Figure 4. Particle size distribution by number of particles obtained by DLS 
studies for calcined nanoparticles S0-3, S2 and S3. 
 
Table 2. Diameter measured by DLS and surface zeta potential of 
calcined nanoparticles S0-3, S2 and S3 materials. 
Sample Particle diameter (nm)  Zeta potential 
(mV) 
S0-3 237.9 ± 30.3 -31.4 
S2 294.7 ± 41.4 -26.5 
S3 426.1 ± 54.2 -17.7 
 
Moreover, the content of 1-propyl-1-H-benzimidazole and 
FITC-Ins in S1, S2 and S3 were determined from 
thermogravimetric and elemental analysis and are detailed in 
Table 3. Besides, energy-dispersive X-ray spectroscopy (EDX) 
clearly showed the presence of C, N, O and Si atoms in these 
solids. In addition, with the aim to estimate the content of CD-
GOx retained in the final solid S3, the absorbance of CD-GOx in 
the solution after the capping process was measured. The 
amount of CD-GOx in the solid S3 was calculated to be 2.11·10-
3 mg g-1 SiO2, representing 2 U of immobilized neoglycoenzyme 
per mg SiO2 according to enzyme activity assays.  
 
Table 3. Content of FITC-Ins and 1-propyl-1-H- benzimidazole  in 
the prepared solids S1, S2 and S3 in mmol g -1 SiO2. 
Sample α FITC-Ins 
 
α1-propyl-1-H-benzimidazole 
S1 - 1.24 
S2 0.20 1.24 
S3 0.17 1.24 
 
Glucose-triggered controlled release of insulin.  
This section evaluates the self-regulated insulin delivery 
from S3 nanoparticles in the presence of glucose. As stated 
above, in humans, the concentration of this saccharide in blood 
is controlled by pancreas, which produces and delivers insulin in 
a finely regulated manner to maintain glucose between 3.5 and 
7 mM.[24] The assessment of S3 in a realistic competitive 
environment was accomplished by using simulated blood 
plasma. In a typical experiment, a suspension of S3 was added 
to simulated blood plasma (pH 7.4) containing glucose at a 
concentration of 50 mM. At the same time a similar suspension 
of S3 in the absence of glucose was used as control. Both 
suspensions were stirred for 20 h under dark and aliquots were 
separated at programmed times and centrifuged in order to 
remove the nanoparticles and isolate the supernatant. FITC-Ins 
release was determined by monitoring the fluorescence intensity 
in the solution (λex = 495 nm; λem = 514 nm). Figure 5 shows the 
delivery profile of FITC-Ins from solid S3 in the presence and in 
the absence of glucose as well as the the FITC-Ins efficiency 
release from S3 in %. The results showed that solid S3 was 
tightly capped and only a 3 % cargo was released after 20 h in 
the control experiment (see curve a in Figure 5). In contrast, the 
presence of 50 mM of glucose induced a remarkable cargo 






delivery (ca. 26% of loaded FITC-Ins) from solid S3 after 20 h 
(curve b). This observation confirms the proposed mechanism, 
in which the glucose oxidation to gluconic acid by the CD-GOx 
promotes cargo release. Also, it is worth mentioning that the 
spherical nanoparticle morphology and the porous structure 
persisted in solid S4 regardless of the FITC-Ins delivery (Figure 
2f). 
 




































Figure 5. Amount of FITC-Ins released (left y axis) and FITC-Ins release 
efficiency (right y axis) from 1 mg of solid S3 as a function of time in the 
absence (curve a) and in the presence of 50 mM of glucose (curve b). 
 
A more in depth, study of cargo release profile from S3 in 
the presence of glucose showed two different delivery trends. At 
shorter times, there was a quick release of insulin whereas at 
longer times the delivery was slower. In order to clarify these two 
different profiles the release kinetic in the presence of glucose at 
shorter times (0 to 4 hours) was fitted to the Higuchi model. 
Higuchi’s model describes drug release as a diffusion process 
based in the Ficks’s law and it is square root time dependent.[51] 
This extended model takes into account the hypotheses that 
initial cargo concentration in the matrix is much higher than 
cargo solubility, that diffusion takes place in only one dimension 
and that cargo diffusivity is constant. This model has been 
broadly and satisfactorily applied to describe drug release 
kinetics from porous matrices.[52,53] Figure 6 shows the fitting of 
the model to data taken in the first hours of the delivery (0 to 4 h). 
The good fitting observed suggested that FITC-Ins delivery from 
S3 pores is essentially a diffusive process. At longer times a 
certain deviation from linearity was found (data not shown). This 
effect (two steps in the release profile) has also been described 
in other kinetic release studies of certain guests (usually drugs) 
from porous carrier materials. 
As a step forward, the release of FITC-Ins from S3 as a 
function of the glucose concentration was studied. In these 
experiments FITC-Ins delivered after 4 h from S3 was studied in 
the glucose concentration range usually found in humans (i.e. up 
to 40 mM) (see Figure 7). The figure shows that in the presence 
of small amounts of glucose the delivered FITC-Ins is low. In 
contrast, when glucose concentration increased the capped 
system reacted delivering a high FITC-Ins dose mimicking 
healthy pancreas response. 



















Figure 6. Amount of FITC-Ins delivered from solid S3 vs. the square root of 
time (t) in simulated human blood plasma.  




















Figure 7. Amount of FITC-Ins released (left y axis) and FITC-Ins release 
efficiency (right y axis) from 1 mg of solid S3 as a function of glucose 
concentration after 4h upon addition of the nanomaterial.  
 
The World Health Organization defines diabetes mellitus 
when fasting plasma glucose level is higher than 126 mg/dL (7.0 
mM) after the intake of 75 g of glucose.[55] This illness, if 
unmedicated, causes glucose peaks up to  40 mM, [56,57] 
especially after food intake. In a healthy person, to counteract 
this effect, blood insulin levels after eating rise more than 10-fold 
from a baseline of around 20-30 pM to 250-300 pM.[24] Taking 
into account that the average blood volume in an adult is 5 L, 
and that S3 delivers ca. 5.91 x 10-9 mol of Ins per mg, (after 2.5 
h for a concentration of glucose 50 mM) it can be estimated that 
the amount of S3 needed to reach insulin levels in the 250-300 
pM range would be as low as ca. 210-233 µg of S3 which is a 
quite low amount probably tolerable in an in vivo scenario. 
An important issue when using delivery systems is that 
they should be ideally selective and deliver the cargo only in the 
presence of a unique target. In our case, when comparing meals 
of various combinations of sugars, proteins and fat, only glucose 
causes blood insulin levels to rise.[24] Thus, it was in our aim to 
demonstrate that the CD-GOx capped material S3 is only 
opened in the presence of glucose and therefore control release 
experiments from S3 were carried out in the presence of other 






saccharides. In particular, the uncapping process in S3 was 
monitored after 4 h in simulated blood plasma containing 
glucose, mannose, fructose, galactose or saccharose at a 
concentration of 10 mM. As shown in Figure 8, S3 material 
shows a notable selectivity for glucose and FITC-Ins delivery 
from S3 in the presence of other saccharides was irrelevant. The 
selective triggering of the FITC-Ins delivery is ascribed to the 
ability of GOx to catalyze the oxidation of glucose to gluconic 












































Figure 8. Release of FITC-Ins from solid S3 in the presence of different 
saccharides (10 mM) after 4 h.  
Conclusions 
In summary, we have developed a new glucose-sensitive 
system for insulin controlled release. Our system consists of 
MSNs with an expanded pore, loaded with FITC-Ins, 
functionalized in the external surface with 1-propyl-1-H-
benzimidazole groups and capped with CD-GOx. Conversion of 
glucose to gluconic acid by GOx induced the dethreading of the 
inclusion complexes and thus cargo release. The prepared 
material demonstrated to be glucose-sensitive by releasing 
FITC-Ins in simulated blood plasma. Moreover, the amount of 
delivered FITC-Ins was dependent of the concentration of 
glucose. Moreover, a relatively few amount of the material was 
able to release suitable amounts of insulin necessary to 
decrease the blood glucose concentration to the regular level. In 
addition, the system demonstrated to be highly selective and 
insulin delivery was only found with glucose whereas other 
saccharides were unable to uncap S3. This is one of the very 
few reported mesoporous supports able to release insulin 
triggered by the presence of glucose. Despite the fact that the 
road from these results to the use of nanoparticles to deliver 
insulin remains long and uncertain, we believe that such 
glucose-responsive nanoparticles able to detect levels of 
glucose in blood and deliver insulin accordingly may open new 
avenues to future designs of new drug-release system of 
potential application for diabetes treatment. 
Experimental Section 
General Techniques: Powder XRD, TG analysis, elemental analysis, 
TEM microscopy and N2 adsorption-desorption techniques were used to 
characterize the prepared materials. X-ray measurements were 
performed on a Bruker AXS D8 Advance diffractometer using Cu-Kα 
radiation. Thermo-gravimetric analysis were carried out on a TGA/SDTA 
851e Mettler Toledo equipment, using an oxidant atmosphere (Air, 80 
mL/min) with a heating program consisting on in a heating ramp of 10° 
per minute from 273 to 373 K followed by an isothermal heating step at 
this temperature for 60 min in a nitrogen atmosphere (80 mL min-1). Then, 
the program was allowed to continue with a dynamic heating segment 
from 373 to 1273 K in an oxidant atmosphere (air, 80 mL min-1) and with 
an isothermal heating step at this temperature for 30 min. TEM images 
were taken with a JEOL TEM-1010 Electron microscope working at 100 
kV. FSEM images and EDX analysis were performed with a Zeiss Ultra-
55 FESEM. N2 adsorption-desorption isotherms were recorded on a 
Micromeritics ASAP2010 automated sorption analyser. The samples 
were degassed at 120 ºC in vacuum overnight. The specific surfaces 
areas were calculated from the adsorption data in the low pressures 
range using the BET model. Pore size was determined following the BJH 
method. Fluorescence spectroscopy was carried out on a Jasco FP-8300 
Spectrometer. 
Chemicals: The chemicals n-cetyltrimethylammonium bromide (CTAB), 
sodium hydroxide (NaOH), fluorescein isothiocyanate (FITC), 3-
iodopropyltrimethoxysilane, tetramethylorthosilicate (TMOS), 1,3,5-
trimethylbenzene (TMB), benzimidazole, triethylamine, insulin human, 
dimethyl sulfoxide (DMSO),  glucose, mannose, fructose, galactose, 
maltose and saccharose were provided by Aldrich. Analytical-grade 
solvents were provided by Scharlab. β-Cyclodextrin-modified glucose 
oxidase (CD-GOx) was synthesized as previously reported.[26] 
Synthesis of MSNs with large pores S0-3: The synthetic procedure of 
MSNs with large pores was carried out according with previous reports 
with slight modifications.[21] 3.94 g of CTAB and 2.28 mL 1M of NaOH  
were dissolved in 800 g ethanol/water (0.4/0.6 = w/w). Then 1.3 mL of 
TMOS were added to the solution with vigorous stirring. After 8h, the 
mixture was kept unstirred overnight. The resulting white precipitate was 
isolated by centrifugation and washed 3 times with ethanol and 3 times 
with distilled water to obtain solid S0-1. The as-synthesised silica 
nanoparticles S0-1 were dispersed in 30 mL of ethanol and the mixture 
was sonicated for 30 min. Subsequently, 20 mL of a 1:1 mixture (v/v) of 
water and TMB was added to the suspension. The mixture was kept in 
an autoclave at 140 °C for 4 days. The resulting solid S0-2 was isolated 
by centrifugation and washed 3 times with ethanol. Finally, the material 
S0-2 was calcined at 550 °C using oxidant atmosphere for 5 h in order to 
remove the organic content and obtain the support S0-3. 
Synthesis of fluorescein isothiocyanate-labeled insulin (FITC-Ins): 
Insulin human was labelled with FITC following previous reports. [10] 2.5 
mL of FITC in DMSO (1 mg mL-1) was added in 5 µL aliquots with gentle 
stirring to a sodium carbonate buffer (0.1 M, pH 9) solution containing 
insulin (4 mg mL-1). The reaction was stirred for 2 h in dark and at room 
temperature. Then, 2.5 mL of NH4Cl 1M was added to the reaction in 
order to quench the excess of FITC. After stirring for an extra hour, the 
solution was dialyzed in phosphate-buffered saline and freeze dried 
yielding FITC labelled insulin. By measuring the absorbance at 495 nm 
and 280 nm the ratio of FITC to insulin was estimated at 1.4. 
Synthesis of S1: The hybrid solid S1 was prepared by adding an excess 
of 3-iodopropyltrimethoxysilane (196 μL, 1 mmol) to a suspension of 500 
mg of S0-3. Then, the suspension was stirred for 5.5 h. The resulting 
solid was filtered, washed with acetonitrile and dried at 70 ºC overnight. 
Following, 500 mg of the resulting material were suspended in a 40 mL of 
a saturated solution of benzimidazole in toluene at 120 ºC and containing 






triethylamine (benzimidazol and triethylamine in a 1:3 proportion). The 
suspension was refluxed and stirred during 72 h. The resulting white 
solid (S1) was filtered off, washed with 10 mL of acetonitrile and dried at 
70 ºC overnight. 
Synthesis of S2: The loading of the pores was carried out by soaking 
400 mg of solid S1 in 40 mL of HCl 0.01 M containing 200 mg of the 
prepared FITC-Ins. The suspension was stirred for 24 h in dark. The 
resulting solid was filtered off to yield S2, washed with 2 mL of HCl 0.01 
M, dried under vacuum and stored in the fridge.   
Synthesis of S3: With the aim to obtain solid S3, 10 mg of S2 were 
suspended in a CD-GOx solution (1 mL, 1.56 mg mL-1) and the 
suspension was stirred at room temperature for 24 h. The final yellow 
solid (S3) was centrifuged (9500 rpm, 4 min, 20 ºC) and washed with 
deionized water at pH 7.5 five times in order to remove the residual dye 
and the free CD-GOx. 
Release studies: In a typical experiment, 10 mg of freshly prepared S3 
solid were suspended in 1.5 mL of deionized water at pH 7.5. 
Subsequently, the suspension was separated in different batches of 150 
μL and each one was diluted to 3 mL with a mixture of simulated human 
blood plasma and deionized water at pH 7.5. At a certain time, an aliquot 
of 0.3 mL of the suspension was separated and centrifuged (8000 rpm, 3 
min). The delivered dye was registered by measuring the FITC-Ins 
emission in the supernatant (λex = 495nm). 
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A novel nanoplatform combining 
diagnosing and drug delivery 
capabilities is presented.  The capped 
system is based on a nanometric 
silica support loaded with FITC-Ins 
and capped with CD-GOx. This 
nanosystem is able to release the 
entrapped FITC-Ins in a controlled 
manner due to the specific enzymatic 
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